Medications for Opioid Use Disorder (MOUD)
Buprenorphine (Suboxone, Sublocade), methadone, naltrexone (Vivitrol). Federally protected access — but commonly denied for residential SUD, long-acting injectables, and dual-diagnosis treatment.
What this class is
MOUD encompasses the FDA-approved medications for opioid use disorder: buprenorphine (sublingual or long-acting injectable), methadone (only at OTP clinics), and naltrexone (oral or extended-release injectable). MOUD is the most effective treatment for OUD; SAMHSA, ASAM, and the AMA universally recommend it. Federal Medicaid is required to cover all approved MOUD products.
Representative drugs
- Buprenorphine sublingual (Suboxone, Subutex, Zubsolv, generics)
- Buprenorphine long-acting injectable (Sublocade, Brixadi)
- Methadone (OTP only)
- Naltrexone oral
- Extended-release naltrexone (Vivitrol)
Common denial patterns
- Step therapy requiring oral sublingual buprenorphine before long-acting injectable
- Residential SUD treatment denial (citing 'lower level of care first')
- Methadone benefit limits
- MHPAEA violations — stricter SUD coverage than medical
Clinical guidelines that win appeals
- SAMHSA TIP 63 — Medications for Opioid Use Disorder
- ASAM National Practice Guideline
- AMA SUD policy
Frequently asked questions
What is medications for opioid use disorder (moud)?
MOUD encompasses the FDA-approved medications for opioid use disorder: buprenorphine (sublingual or long-acting injectable), methadone (only at OTP clinics), and naltrexone (oral or extended-release injectable). MOUD is the most effective treatment for OUD; SAMHSA, ASAM, and the AMA universally recommend it. Federal Medicaid is required to cover all approved MOUD products.
What are the common denial patterns?
Step therapy requiring oral sublingual buprenorphine before long-acting injectable; Residential SUD treatment denial (citing 'lower level of care first'); Methadone benefit limits; MHPAEA violations — stricter SUD coverage than medical.
Which clinical guidelines support appeals?
SAMHSA TIP 63 — Medications for Opioid Use Disorder; ASAM National Practice Guideline; AMA SUD policy.
Related
- Substance use disorder treatment (SUD/MOUD)MOUD (Suboxone, Sublocade, methadone, Vivitrol), residential, detox
- Mental health & behavioral healthInpatient psych, residential, PHP/IOP, therapy, TMS, Spravato
- Antifibrotic agentsPirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pul
- Biologic drugs (mAbs and biosimilars)Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheu
- BiosimilarsFDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use
- Direct oral anticoagulants (DOACs)Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfar
Sources
Appeal a medications for opioid use disorder (moud) denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com